JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8885 Ro 3306
4 Citation

Target: Cyclin-Dependent Kinases

Summary: An ATP-competitive, potent CDK1 inhibitor

insoluble in EtOH; insoluble in H2O; ≥4.39 mg/mL
B5881 RI-2

Target: RAD51

Summary: Optimized reversible RAD51 inhibitor

≥21.65 mg/mL
B6962 CMPD-1

Target: Microtubules/Tubulins|MK2

Summary: inhibitor of p38α-mediated MK2a phosphorylation

<34.94 mg/mL
A8310 PF-562271
1 Citation

Target: FAK|Pyk2

Summary: ATP-competitive FAK inhibitor, reversible

≥25.35 mg/mL
A8320 PF-00562271

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor,potent and ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥11.1 mg/mL
A8336 KU-60019
2 Citation

Target: ATM/ATR

Summary: ATM kinase inhibitor,potent and selective

≥27.4 mg/mL
A8345 PF-562271 HCl

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor

≥26.35 mg/mL
A8375 AZD8931 (Sapitinib)

Target: EGFR|ErbB

Summary: ErbB inhibitor

≥23.7 mg/mL
A8440 GSK1838705A

Target: Insulin and Insulin-like Receptors|ALK

Summary: IGF-IR/IR/ALK inhibitor, ATP-competitive

≥26.65 mg/mL
A8441 GSK461364
3 Citation

Target: PLK

Summary: Plk1 inhibitor